

## Press Release

Heerlen, 20 September 2012

DSM, Corporate Communications  
e-mail: [media\\_relations@dsm.com](mailto:media_relations@dsm.com)  
[www.dsm.com](http://www.dsm.com)

25E

### DSM in exclusive discussions to acquire Cargill's cultures and enzymes business

Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it is in exclusive discussions with Cargill which may, or may not result in the acquisition of Cargill's cultures and enzymes business by DSM.

The cultures and enzymes business of Cargill is a global leading manufacturer of cultures and enzymes for the dairy and meat industries with manufacturing operations in Wisconsin (USA) and France. It has a strong pipeline of new products built on three pillars of technology: culture texture toolbox, fast acidification for cheese yield improvements and culture flavor systems. The business generates net sales of about €45 million per year with approximately 200 employees.

The global market for cultures and enzymes is valued at over €1 billion, growing steadily at more than 5% per annum. A possible combination of the Cargill cultures and enzymes business with the dairy business of DSM Food Specialties would be highly complementary creating a strong global player and enabling DSM to propel sales growth as well as capture sizable synergies in global manufacturing footprint, customer reach as well as innovation capabilities in biotechnology and SG&A.

A successful acquisition of the Cultures and Enzymes business of Cargill would be the eighth acquisition in the Nutrition cluster since DSM announced its corporate strategy DSM in motion: *driving focused growth* in September 2010. These acquisitions form an integral part of DSM's strategy for its Nutrition cluster and will contribute to the current and future growth of DSM's attractive portfolio in health, nutrition and materials.

Hans-Christian Ambjerg, President DSM Food Specialties, commented: *"This acquisition would be another great step in achieving our ambitious growth strategy. Combining both businesses would allow us to serve our customers faster with one of the most versatile offerings in Cultures and Enzymes in the global dairy industry. We have great respect for the knowledge and expertise of the people at Cargill."*

Both companies are now engaging in the information and consultation process with employee representative bodies in the relevant countries. Further information will be announced in due course.

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at [www.dsm.com](http://www.dsm.com).

Page 2 of 2  
DSM in exclusive discussions to acquire Cargill's cultures  
and enzymes business  
20 September 2012

For more information:

DSM Corporate Communications  
Herman Betten  
tel. +31 (0) 45 5782017  
fax +31 (0) 45 5740680  
e-mail [media.relations@dsm.com](mailto:media.relations@dsm.com)

DSM Investor Relations  
Dave Huizing  
tel. +31 (0) 45 5782864  
fax +31 (0) 10 4590275  
e-mail [investor.relations@dsm.com](mailto:investor.relations@dsm.com)

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.